Robust neuroprotective effects of intranasally delivered iNOS siRNA encapsulated in gelatin nanoparticles in the postischemic brain

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 5, 2016, Pages 1219-1229

  Kim, Il Doo ^a   Sawicki, Elizabeth ^b   Lee, Hye Kyung ^a   Lee, Eun Hwa ^c   Park, Heon Joo ^a   Han, Pyung Lim ^c   Kim, Kyekyoon Kevin ^b   Choi, Hyungsoo ^b   Lee, Ja Kyeong ^a  

^a Inha University School of Medicine   (South Korea)

^b University of Illinois at Urbana Champaign   (United States)

^c Ewha Womans University   (South Korea)

Author keywords

Gelatin nanoparticles; INOS; Intranasal delivery; MCAO; SiRNA

Indexed keywords

ENZYME ACTIVITY; NANOPARTICLES;

GELATIN NANOPARTICLES; INOS; INTRANASAL; MCAO; SIRNA;

BRAIN;

GELATIN; GLUTARALDEHYDE; INDUCIBLE NITRIC OXIDE SYNTHASE; NANOPARTICLE; SMALL INTERFERING RNA; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CORPUS STRIATUM; CROSS LINKING; GENE DELIVERY SYSTEM; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NANOENCAPSULATION; NEUROPROTECTION; NONHUMAN; OLFACTORY BULB; RAT; ANIMAL; BRAIN; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRANASAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN; GELATIN; INFARCTION, MIDDLE CEREBRAL ARTERY; NANOPARTICLES; NEUROPROTECTIVE AGENTS; RATS; RNA, SMALL INTERFERING;

EID: 84963655398     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.01.002     Document Type: Article

References (42)

1. Leung R.K., Whittaker P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005, 107:222-239.
2. Burnett J.C., Rossi J.J. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012, 19:60-71.
3. Behlke M.A. Progress towards in vivo use of siRNAs. Mol Ther 2006, 13:644-670.
4. Glebova K.V., Marakhonov A.V., Baranova A.V., Skoblov M.I. Types of non-viral delivery systems of small interfering RNA. Mol Biol (Mosk) 2012, 46:387-401.
5. Ikada Y., Tabata Y. Protein release from gelatin matrices. Adv Drug Deliv Rev 1998, 31:287-301.
6. Barbetta A., Dentini M., Zannoni E.M., De Stefano M.E. Tailoring the porosity and morphology of gelatin-methacrylate polyHIPE scaffolds for tissue engineering applications. Langmuir 2005, 21:12333-12341.
7. Ishikawa H., Nakamura Y., Jo J., Tabata Y. Gelatin nanospheres incorporating siRNA for controlled intracellular release. Biomaterials 2012, 33:9097-9104.
8. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000, 11:1-18.
9. Liu X.F., Fawcett J.R., Thorne R.G., DeFor T.A., Frey W.H. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 2001, 187:91-97.
10. Ross T.M., Martinez P.M., Renner J.C., Thorne R.G., Hanson L.R., Frey W.H. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 2004, 151:66-77.
11. Kim I.D., Shin J.H., Kim S.W., Choi S., Ahn J., Han P.L., et al. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther 2012, 20:829-839.
12. Kim I.D., Shin J.H., Lee H.K., Jin Y.C., Lee J.K. Intranasal delivery of HMGB1-binding heptamer peptide confers a robust neuroprotection in the postischemic brain. Neurosci Lett 2012, 525:179-183.
13. Joachim E., Kim I.D., Jin Y., Kim K.K., Lee J.K., Choi H. Gelatin nanoparticles enhance the neuroprotective effects of intranasally administered osteopontin in rat ischemic stroke model. Drug Deliv Transl Res 2014, 4:395-399.
14. Tanaka K., Gotoh F., Gomi S., Takashima S., Mihara B., Shirai T., et al. Inhibition of nitric oxide synthesis induces a significant reduction in local cerebral blood flow in the rat. Neurosci Lett 1991, 127:129-132.
15. Toda N., Ayajiki K., Okamura T. Cerebral blood flow regulation by nitric oxide: recent advances. Pharmacol Rev 2009, 61:62-97.
16. Huang Z., Huang P.L., Panahian N., Dalkara T., Fishman M.C., Moskowitz M.A. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994, 265:1883-1885.
17. Zhao X., Haensel C., Araki E., Ross M.E., Iadecola C. Gene-dosing effect and persistence of reduction in ischemic brain injury in mice lacking inducible nitric oxide synthase. Brain Res 2000, 872:215-218.
18. Iadecola C., Zhang F., Xu X. Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol 1995, 268:R286-R292.
19. Iadecola C., Zhang F., Casey R., Nagayama M., Ross M.E. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997, 17:9157-9164.
20. Prüss H., Prass K., Ghaeni L., Milosevic M., Muselmann C., Freyer D., et al. Inducible nitric oxide synthase does not mediate brain damage after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2008, 28:526-539.
21. Coester C.J., Langer K., van Briesen H., Kreuter J. Gelatin nanoparticles by two step desolvation--a new preparation method, surface modifications and cell uptake. J Microencapsul 2000, 17:187-193.
22. Kim J.B., Sig Choi J., Yu Y.M., Nam K., Piao C.S., Kim S.W., et al. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006, 26:6413-6421.
23. Chen J., Sanberg P.R., Li Y., Wang L., Lu M., Willing A.E., et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001, 32:2682-2688.
24. Candelario-Jalil E., Yang Y., Rosenberg G.A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009, 158:983-994.
25. Jin Y., Kim I.Y., Kim I.D., Lee H.K., Park J.Y., Han P.L., et al. Biodegradable gelatin microspheres enhance the neuroprotective potency of osteopontin via quick and sustained release in the post-ischemic brain. Acta Biomater 2014, 10:3126-3135.
26. Galea E., Golanov E.V., Feinstein D.L., Kobylarz K.A., Glickstein S.B., Reis D.J. Cerebellar stimulation reduces inducible nitric oxide synthase expression and protects brain from ischemia. Am J Physiol 1998, 274:H2035-H2045.
27. Chen Z.B., Huang D.Q., Niu F.N., Zhang X., Li E.G., Xu Y. Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB. J Cereb Blood Flow Metab 2010, 30:1356-1365.
28. Amantea D., Russo R., Gliozzi M., Fratto V., Berliocchi L., Bagetta G., et al. Early upregulation of matrix metalloproteinases following reperfusion triggers neuroinflammatory mediators in brain ischemia in rat. Int Rev Neurobiol 2007, 82:149-169.
29. Rosenberg G.A., Estrada E.Y., Dencoff J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998, 29:2189-2195.
30. Heo J.H., Lucero J., Abumiya T., Koziol J.A., Copeland B.R., del Zoppo G.J. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999, 19:624-633.
31. Yang Y., Estrada E.Y., Thompson J.F., Liu W., Rosenberg G.A. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007, 27:697-709.
32. Kozlovskaya L., Abou-Kaoud M., Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release 2014, 189:133-140.
33. Alex A.T., Joseph A., Shavi G., Rao J.V., Udupa N. Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery. Drug Deliv 2015, 25:1-10.
34. Liu Z., Jiang M., Kang T., Miao D., Gu G., Song Q., et al. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials 2013, 34:3870-3881.
35. Seju U., Kumar A., Sawant K.K. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater 2011, 7:4169-4176.
36. Harmon B.T., Aly A.E., Padegimas L., Sesenoglu-Laird O., Cooper M.J., Waszczak B.L. Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain. Gene Ther 2014, 21:514-521.
37. Kanazawa T., Akiyama F., Kakizaki S., Takashima Y., Seta Y. Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials 2013, 34:9220-9226.
38. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127:481-496.
39. Scranton R.A., Fletcher L., Sprague S., Jimenez D.F., Digicaylioglu M. The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS. PLoS One 2011, 6:e18711.
40. Lochhead J.J., Wolak D.J., Pizzo M.E., Thorne R.G. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J Cereb Blood Flow Metab 2015, 35:371-381.
41. van den Berg M.P., Verhoef J.C., Romeijn S.G., Merkus F.W. Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm 2004, 58:131-135.
42. Danielyan L., Schäfer R., von Ameln-Mayerhofer A., Buadze M., Geisler J., Klopfer T., et al. Intranasal delivery of cells to the brain. Eur J Cell Biol 2009, 88:315-324.